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Abstract
Background: The n-3 polyunsaturated fatty acids eicosapentaenoic acid and docosahexaenoic acid, which are
present in fish, are protective against myocardial infarction. However, fish also contains methylmercury, which
influences the risk of myocardial infarction, possibly by generating oxidative stress. Methylmercury is metabolized
by conjugation to glutathione, which facilitates elimination. Glutathione is also an antioxidant. Individuals with
certain polymorphisms in glutathione-related genes may tolerate higher exposures to methylmercury, due to faster
metabolism and elimination and/or better glutathione-associated antioxidative capacity. They would thus benefit
more from the protective agents in fish, such as eicosapentaenoic+docosahexaenoic acid and selenium. The
objective for this study was to elucidate whether genetic polymorphisms in glutathione-related genes modify the
association between eicosapentaenoic+docosahexaenoic acid or methylmercury and risk of first ever myocardial
infarction.
Methods: Polymorphisms in glutathione-synthesizing (glutamyl-cysteine ligase catalytic subunit, GCLC and
glutamyl-cysteine ligase modifier subunit, GCLM) or glutathione-conjugating (glutathione S-transferase P, GSTP1)
genes were genotyped in 1027 individuals from northern Sweden (458 cases of first-ever myocardial infarction and
569 matched controls). The impact of these polymorphisms on the association between erythrocyte-mercury
(proxy for methylmercury) and risk of myocardial infarction, as well as between plasma eicosapentaenoic
+docosahexaenoic acid and risk of myocardial infarction, was evaluated by conditional logistic regression. The
effect of erythrocyte-selenium on risk of myocardial infarction was also taken into consideration.
Results: There were no strong genetic modifying effects on the association between plasma eicosapentaenoic
+docosahexaenoic acid or erythrocyte-mercury and risk of myocardial infarction risk. When eicosapentaenoic
+docosahexaenoic acid or erythrocyte-mercury were divided into tertiles, individuals with GCLM-588 TT genotype
displayed a lower risk relative to the CC genotype in all but one tertile; in most tertiles the odds ratio was around
0.5 for TT. However, there were few TT carriers and the results were not statistically significant. The results were
similar when taking plasma eicosapentaenoic+docosahexaenoic acid, erythrocyte-selenium and erythrocyte-mercury
into account simultaneously.
Conclusions: No statistically significant genetic modifying effects were seen for the association between plasma
eicosapentaenoic+docosahexaenoic acid or erythrocyte-mercury and risk of myocardial infarction. Still, our results
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Background
The toxic compound methylmercury (MeHg) from fish
may increase the risk of myocardial infarction (MI), pos-
sibly due to induction of oxidative stress, a risk factor
for MI. High mercury (Hg) levels in hair (proxy for
MeHg retention) [1,2] and toenails (proxy for MeHg)
[3] have been associated with an increased risk of MI.
However, high Hg levels in erythrocytes (Ery-Hg; proxy
for MeHg) have been associated with a decreased risk of
MI in some studies [4,5]. This discrepancy between stu-
dies and populations may partly be explained by differ-
ent MeHg exposure levels in different studies. However,
genetic differences between individuals and populations
may explain some of these discrepancies; some indivi-
duals may have a genetic setup giving a more beneficial
MeHg metabolism, resulting in a faster MeHg-elimina-
tion [6,7] and/or differences in capacity to detoxify reac-
tive oxygen species induced by MeHg. Individuals with
a more beneficial MeHg metabolism and/or a better
capacity to detoxify reactive oxygen species may be able
to tolerate higher exposures to MeHg. Subsequently,
they would benefit more from protective agents in fish,
the major source of MeHg exposure. Protective agents
include the n-3 polyunsaturated long chain fatty acids
eicosapentaenoic acid (EPA) and docosahexaenoic acid
(DHA) (their sum referred to as EPA+DHA), which has
antiatherogenic, antithrombotic and antiarrhythmic
properties [8,9], as well as selenium (Se), which may
protect against MI due to its presence in the antioxidant
enzyme glutathione peroxidase.
MeHg is eliminated in the bile as a glutathione (GSH)
conjugate [10,11]. The rate-limiting enzyme for GSH
synthesis is glutamyl-cysteine ligase (GCL), which is
composed of a catalytic subunit (GCLC [Unigene:
Hs.654465] [12]) and a modifier subunit (GCLM [Uni-
gene: Hs.315562]). The glutathione S-transferases
(GSTs), which conjugate GSH to a wide variety of elec-
trophilic compounds [13,14], may also affect the meta-
bolism of MeHg. Polymorphisms with a functional
impact in genes coding for GSH-synthesizing (GCLC,
GCLM) or GSH-conjugating (GSTs) enzymes may thus
influence the elimination capacity. Polymorphisms
affecting GSH production (lower promoter activity for
the variant alleles) have been found in both subunits; a
C®T nucleotide substitution at position -129 in GCLC
(GCLC-129) [15,16] and a C®T nucleotide substitution
at position -588 in GCLM [17]. Glutathione-S-
transferase pi (GSTP1 [Unigene [12]: Hs.523836]) exhi-
bits a number of genetic polymorphisms, of which the
Ile105Val and Ala114Val amino acid substitutions both
have been associated with differences in enzyme activity
and substrate preferences [18-20]. Furthermore, GSH is
an antioxidative agent, and polymorphisms in GCLC,
GCLM and GSTP1 may thus modify the MeHg-induced
oxidative damage.
In our previous study [7], we evaluated the genetic
impact on MeHg metabolism. This study did not
include any MI cases and consisted of different study
subjects than the present study. We found that carriers
of the variant alleles for the GSTP1 polymorphisms
GSTP1-105 or GSTP1-114 had lower levels of Ery-Hg at
high plasma EPA+DHA, compared with individuals with
no variant alleles, indicating a faster elimination of
MeHg for variant-allele carriers. Also, TT homozygotes
for the GCLM-588 polymorphism demonstrated higher
Ery-Hg than the other GCLM-588 genotypes. Poly-
morphisms in GCLC, GCLM and/or GSTP1 have been
associated with body burden of Hg in other studies
[6,21,22].
The present study is an extension of a study by
Wennberg et al [5], which evaluated the impact of P-
EPA+DHA and Ery-Hg on MI risk in this study popula-
tion. The study by Wennberg et al. found that Ery-Hg
was statistically significantly associated with a decreased
risk of MI, while EPA+DHA in plasma indicated a
decreased risk of MI (not statistically significant). The
aim of the present study was to elucidate whether poly-
morphisms in genes potentially involved in MeHg meta-
bolism and/or antioxidant defense can modify the
association between EPA+DHA or Ery-Hg and MI risk.
The effect of erythrocyte-Se (Ery-Se) on MI risk was
also considered.
Methods
Study population
The study population is part of an individually matched
case-control study nested within three prospective
health surveillance cohorts in Västerbotten, Northern
Sweden: the Västerbotten Intervention Program (VIP),
the WHO’s Multinational Monitoring of Trends and
Determinants in Cardiovascular Disease (MONICA)
Study in northern Sweden, and the Mammography
Screening Project (MSP). Both VIP and MONICA are
health examination programs for CVD and diabetes.
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more thoroughly in Wennberg et al. [5]. Medical history
and lifestyle information was obtained at baseline in
1987 - 1999 (Table 1). Venous blood was sampled and
erythrocytes, serum and plasma were separated and
stored in a biobank at -80°C. Controls were matched to
the cases for first ever MI (one control for each male
case and two for each female case) for sex, age (±2
years), date of health survey (±4 months) and geographi-
cal region. Cases and controls were excluded if previous
MI, stroke, or malignant disease could not be excluded
according to the questionnaire or case records. Erythro-
cytes and DNA were available from 1027 individuals
(458 cases and 569 controls); 42 cases and 56 controls
were missing compared with Wennberg et al. [5], due to
lack of samples for DNA extraction. Plasma was avail-
able from 916 individuals (408 cases and 508 controls).
Data on smoking was missing for 39 individuals, and
data on apolipoprotein B/A1 ratio (ApoB/ApoA1) was
missing for 3 individuals. Smoking habits were classified
into “daily smoking” or “nonsmoking” (including pre-
vious smokers and occasional smokers). The study was
approved by the Regional Ethics Committee of Umeå
University. Participants gave written informed consent
prior to the study.
Measurement of Ery-Hg, Ery-Se and P-EPA+DHA
The determination of Ery-Hg was made in acid-digested
samples using cold vapor atomic fluorescence spectro-
metry [5,7,23]. Plasma fatty acids were separated by gas-
liquid chromatography after separation of the lipids by
thin layer chromatography and transmethylation [24].
Plasma EPA+DHA (P-EPA+DHA) was calculated as the
percent in plasma phospholipids [4,25]. APOA1 and
APOB were measured by immunoturbidimetry, while
Ery-Se was measured by inductively coupled plasma
mass spectrometry (ICP-MS; Thermo × 7; Thermo Ele-
mental, Winsford, United Kingdom).
More detailed information, such as limit of detection,
coefficients of variance, and reference material are thor-
oughly described in Wennberg et al. [5].
Genotype analyses
The Taqman allelic discrimination assay (ABI 7000,
Applied Biosystems, Foster City, CA, USA) was per-
formed to analyze all four single nucleotide polymorph-
isms (SNPs) separately; GCLC-129, GCLM-588, GSTP1-
105 and GSTP1-114 [6,7]. There was a total agreement
between the original and repeat genotyping runs in all
of the four SNPs analyzed. Genotype frequencies as well
as the ID numbers (rs numbers [26]) for the polymorph-
isms are presented in Table 2.
Statistical analysis
Hardy-Weinberg equilibrium was tested for the controls
using the conventional Chi-square test. Because the
effects of P-EPA+DHA, Ery-Se and Ery-Hg on MI risk
were in the same direction for men and women [5],
both genders were combined in the multivariate ana-
lyses. Due to a lot of missing data for some of the back-
ground variables (especially for females), we only
considered adjustments for age, smoking, BMI, year of
sampling, and ApoB/ApoA1. In total, we employed four
genetic markers (GCLC-129, GCLM-588, GSTP1-105
and GSTP1-114). Effects of dual-polymorphisms for the
GSTP1 gene (GSTP1-105 and GSTP1-114)w e r ea l s o
analyzed, where genotype was categorized as the total
number of variant alleles for both polymorphisms. Indi-
viduals with two or more variant alleles were pooled
Table 1 Descriptive data of the study population
Controls Cases
N Mean SD Range N Mean SD Range
Ery-Hg (μg/l) 569 4.9 5.1 0.19-
81
458 4.5 5.7 0.010-
87
P-EPA+DHA (%) 508 6.2 1.6 2.8-14 408 6 1.5 3.2-15
Ery-Se (μg/l) 568 130 37 75-710 458 130 22 72-210
ApoB/apoA1 567 0.8 0.26 0.14-
2.1
457 0.95 0.25 0.21-2.1
BMI (kg/m
2) 435 26 4 18-49 378 27 4 18-57
Smokers 555 19% 433 42%
Fish (meals/
week)
427 1.3 0.79 0.0-5.5 354 1.2 0.94 0.0-8.0
-lean fish 431 0.72 0.67 0.0-6.5 365 0.68 0.58 0.0-4.0
-fat fish 433 0.57 0.47 0.0-4.0 361 0.58 0.58 0.0-4.0
Abbreviations: SD, standard deviation; Ery-Hg, erythrocyte total mercury
concentration; Ery-Se, erythrocyte selenium concentration.
Table 2 Genotype frequencies for GCLC-129, GCLM-588,
GSTP1-105 and GSTP1-114
Gene Polymorphism Genotype Frequency (%)
GCLC -129C/T CC 86
rs17883901 CT 13
TT 0.5
GCLM -588C/T CC 75
rs41303970 CT 22
TT 2.9
GSTP1 Ile105Val Ile/Ile 51
rs1695 Ile/Val 40
Val/Val 8.8
GSTP1 Ala114Val Ala/Ala 82
rs1138272 Ala/Val 17
Val/Val 1.4
Abbreviations: GCLC, glutamyl-cysteine ligase catalytic subunit; GCLM, glutamyl-
cysteine ligase modifier subunit; GSTP1, glutathione-S-transferase Pi 1.
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variables in all analyses. Since this study is an extension
of the study by Wennberg et al [5], P-EPA+DHA and
Ery-Hg were evaluated in a similar fashion - divided
into tertiles - as in Wennberg et al [5].
A schematic overview of the statistical analyses are
shown in Figure 1. For all analyses, a univariate condi-
tional logistic regression model (unadjusted model),
based on the matched case-control sets was performed,
as well as a multivariate logistic regression model
(adjusted model), including covariates that had a p-value
< 0.05.
Firstly, we evaluated whether genotype in itself had
any effect on MI risk (I in Figure 1). For each poly-
morphism, the group with the most common homozy-
gous genotype was used as reference. For the GSTP1-
105 and GSTP1-114 combination, the group with indivi-
duals with 0 variant alleles was used as reference.
Secondly, we evaluated whether the association
between P-EPA+DHA and MI risk was modified by gen-
otype due to its potential impact on MeHg metabolism
(II in Figure 1). Genetic factors may have an impact on
MeHg metabolism, resulting in an individual variation
regarding retention and elimination of MeHg at similar
exposure levels. Differences in retention/elimination lead
to differences in the amount of MeHg that has the
opportunity to target vulnerable organs and cause toxic
effects that may increase the risk of MI. In order to
evaluate this, P-EPA+DHA can be used as a proxy for
intake of MeHg, since P-EPA+DHA correlates with the
body burden of MeHg. P-EPA+DHA was stratified into
three groups, according to tertiles in the controls (0-
5.39, 5.40-6.68, and 6.69-15%, respectively). A univariate
and a multivariate conditional logistic regression model
were run for each stratum. The group consisting of the
most common homozygotes at the lowest P-EPA+DHA
tertile was used as reference.
Thirdly, we evaluated whether the association between
Ery-Hg and MI risk was modified by genotype, due to
its potential role in protection against oxidative stress
(III in Figure 1). Ery-Hg was stratified according to ter-
tiles in the controls (0-2.81, 2.82-4.79, and 4.83-87 μg/l,
respectively). The tertile boundaries differed somewhat
from Wennberg et al. [5], due to a different number of
individuals. A univariate and multivariate conditional
logistic regression model were run for each stratum.
The group consisting of the most common homozygotes
at the lowest Ery-Hg tertile was used as reference.
Fourthly, we evaluated whether the effect of Ery-Hg
on MI risk was modified by genotype (IV in Figure 1),
when adjustments were done for P-EPA+DHA and Ery-
Se.
Because of the low allelic frequencies and similar
effects of some genotypes, the heterozygotes and homo-
zygous variant genotypes for the same gene were pooled
in all analyses for GCLC-129 and GSTP1-114.
All statistical analyses were performed using the soft-
ware SPSS (version 15; SPSS, Chicago, IL, USA). All
tests were two-sided and p ≤ 0.05 was considered statis-
tically significant.
Results
When genotype was not taken into account, P-EPA
+DHA indicated a decreasing MI risk (p = 0.15), while
Ery-Hg was statistically significantly associated with
decreasing MI risk (p = 0.014) (Wald test for univariate
analyses for the trichotomized biomarkers).
There were significant effects on MI risk by smoking
(OR 3.2, 95% CI 2.4, 4.5) and ApoB/ApoA1 (OR 12.7,
95% CI 6.7, 24) and these two variables were thus
included in the multivariate analyses.
All polymorphisms were in Hardy-Weinberg equili-
brium (analyzed for controls only) except for GCLM-
588 (p = 0.030).
When evaluating the effect of genotype alone on MI
risk (I in Figure 1), no significant results were seen. For
example, the adjusted odds ratio (OR) for the GCLM-
588 TT genotype (GCLM-588 CC was used as reference)
was 0.60 (95% CI 0.24, 1.5).
I. Genotype MI
II. P-EPA+DHA MI
Genotype
III. Ery-Hg MI
Genotype
IV. Ery-Hg MI
Genotype
Adjusted for P-EPA+DHA and Ery-Se
Figure 1 Schematic overview of the statistical analyses
performed. Abbreviations: MI, myocardial infarction; Ery-Hg,
erythrocyte total mercury concentration; Ery-Se, erythrocyte
selenium concentration).
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ing effect of the associations between P-EPA+DHA or
Ery-Hg and MI risk (Figures 2 and 3). The variant
homozygotes (TT)f o rt h eGCLM-588 polymorphism
had a lower MI risk relative to wildtype homozygotes
(CC) in all P-EPA+DHA and Ery-Hg tertiles (Figures 2,
graph C and 3, graph C). The ORs for TT were around
0.5 in most tertiles. However, this was not statistically
significant and it was based on few individuals with the
TT genotype. Among the controls, the GCLM TT
carriers demonstrated a mean Ery-Hg level of 5.4 μg/l
among the controls compared to 4.9 μg/l among the
GCLM CC+CT carriers (p-value = 0.65, ANOVA).
For GSTP1 (combination of GSTP1-105 and GSTP1-
114), carriers of two or more variant alleles showed the
lowest risk in all Ery-Hg tertiles (Figure 3, graph F).
However, the differences were not statistically
significant.
All analyses gave similar genetic modifying effects on
the association between Ery-Hg and MI risk when
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Figure 2 Genetic impact on the association between P-EPA+DHA and MI risk. Risk of MI (Odds Ratio, OR) with 95% confidence intervals
(CI) for different genotypes in the P-EPA+DHA tertiles. The reference group is the most common homozygote in the lowest P-EPA+DHA tertile.
ORs are adjusted for smoking and ApoB/ApoA1 ratio. The tertile boundaries are 0-5.39, 5.40-6.68, and 6.69-15%.
a Number of individuals in each
group.
b Number of variant alleles.
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compared with when no adjustments for P-EPA+DHA
and Ery-Se were done (data not given here).
Discussion
Similar patterns as in Wennberg et al. [5] were seen
regarding the associations between Ery-Hg and P-EPA
+DHA, respectively, and MI risk. This is not surprising,
since the study populations are, largely, the same in
both studies. It is also in accordance with a previous,
smaller study in the same region [4]. The protective
effect of P-EPA+DHA is in concordance with numerous
other studies. The association between high Ery-Hg and
low MI risk is most likely because Ery-Hg is a marker of
fish intake.
We found that the polymorphisms studied had no
effect on MI risk by themselves. When P-EPA+DHA or/
and Ery-Hg was taken into account, the GCLM-588 TT
genotype had a lower risk relative to the CC genotype in
all P-EPA+DHA or Ery-Hg tertiles except for one (inter-
mediate tertile for Ery-Hg) (ORs generally around 0.5),
but these findings were not statistically significant. The
lack of statistically significant results in this study may
be due to a small number of individuals for some geno-
types, in particular GCLM-588 TT, yielding a too low
power to detect statistically significant effects. The effect
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Figure 3 Genetic impact on the association between Ery-Hg and MI risk. Risk of MI (OR) with 95% CI for different genotypes in the Ery-Hg
tertiles. The reference group is the most common homozygote in the lowest Ery-Hg tertile. ORs are adjusted for smoking and ApoB/ApoA1
ratio. The tertile boundaries are 0-2.81, 2.82-4.79, and 4.83-87 μg/l.
a Number of individuals in each group.
bNumber of variant alleles.
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a n tf r o mt h eCT genotype, which prevented us from
pooling these two genotypes. In our previous study, the
GCLM-588 TT genotype demonstrated the highest levels
of Ery-Hg [7]. The GCLM-588 TT genotype had the
highest levels of Ery-Hg also among the controls in this
study, although this was not significant. GCLM-588 TT
carriers displayed the lowest risk of MI in each P-EPA
+DHA tertile in this study. However, it is important to
note that this interpretation is based on few individuals
and needs to be confirmed.
The GCLM-588 was in Hardy-Weinberg disequilibrium.
The allele frequencies reported here were similar to
another study, analyzing Danish and Swiss populations,
where Hardy-Weinberg equilibrium was reported [27].
The preceding gene-environment studies for MeHg with
individuals from the same geographical area [6,7] also
showed linkage disequilibrium, while we observed equili-
brium in other studies by our group, employing the same
methods, but in other populations [21,28]. Therefore, the
linkage disequilibrium may be population-specific.
To our knowledge, no other studies have assessed
gene-environment interactions (for any gene) on the
association between MeHg or n-3 polyunsaturated fatty
acids and MI risk. There may, however, also be other
genetic traits that can influence these associations, e.g.
polymorphisms in other GSH-related genes, such as glu-
tathione peroxidase (GPX1),g l u t a r e d o x i n(GLRX),
gamma-glutamyl transferase 1 (GGT1),o ri na n yo ft h e
other GSTs. It is also possible that thioredoxin (TXN)
and TXN-related genes affect the metabolism of MeHg
[29]. In addition to the genes we studied, there may be
an influence of other genes involved in oxidative stress,
such as catalase (CAT), paroxonases (PONs) and super-
oxide dismutase (SOD).
A number of studies have investigated the genetic
impact on MI risk. Some included genes potentially
involved in protection against oxidative stress: the
GCLM-588 T-allele has been associated with a higher
risk of MI (non-lethal cases [17]). The T-allele showed a
lower promoter activity in response to oxidants, and the
increase of mRNA expression in response to oxidants
was significantly lower among CT subjects, compared to
CC subjects. The variant allele of GCLC-129 has also
been associated with MI [16]. However, none of these
findings was confirmed in our study.
Conclusions
There was no statistically significant genetic modifying
impact on the association between P-EPA+DHA or Ery-
Hg and MI risk. Still, our results indicate that the rela-
tively rare GCLM-588 TT genotype may have an impact,
but a larger study is necessary for testing this
hypothesis.
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